Sophie Mineau1, Robert Kozak1, Melissa Kissoon1, Aimee Paterson1, Anthony Oppedisano1, Firas Douri1, Kate Gogan1, Barbara M Willey1, Allison McGeer1, Susan M Poutanen2. 1. Department of Microbiology (Mineau, Kozak, Kissoon, Paterson, Oppedisano, Douri, Gogan, Willey, McGeer, Poutanen), University Health Network/Sinai Health System, Toronto, Ont.; Centre intégré de santé et de services sociaux de Chaudière-Appalaches (Mineau), Sainte-Marie, Que.; Lawrence Park Collegiate Institute (Gogan); Departments of Laboratory Medicine and Pathobiology and of Medicine (McGeer, Poutanen), University of Toronto, Toronto, Ont. 2. Department of Microbiology (Mineau, Kozak, Kissoon, Paterson, Oppedisano, Douri, Gogan, Willey, McGeer, Poutanen), University Health Network/Sinai Health System, Toronto, Ont.; Centre intégré de santé et de services sociaux de Chaudière-Appalaches (Mineau), Sainte-Marie, Que.; Lawrence Park Collegiate Institute (Gogan); Departments of Laboratory Medicine and Pathobiology and of Medicine (McGeer, Poutanen), University of Toronto, Toronto, Ont. susan.poutanen@sinaihealthsystem.ca.
Abstract
BACKGROUND: Enterobacteriaceae that produce extended-spectrum β-lactamase (ESBL) have emerged as a serious threat, with variable rates depending on geographic region. We determined the prevalence of ESBL-producing Escherichia coli, Klebsiella pneumoniae, K. oxytoca and Proteus mirabilis in bloodstream infections in Toronto from 2006 through 2016. METHODS: All patients with E. coli, K. pneumoniae, K. oxytoca and P. mirabilis isolated from blood in a tertiary care microbiology laboratory in Toronto between 2006 and 2016 (1 isolate per species per patient per year) were included in this retrospective cohort study. Organisms were identified by conventional methods, and susceptibility testing was performed according to Clinical and Laboratory Standards Institute standards. Screening for ESBL and phenotypic confirmatory testing were done with a modified Clinical and Laboratory Standards Institute method. ST131 clonal type was determined by means of an established protocol. RESULTS: The proportion of ESBL-producing E. coli isolates increased significantly between 2006 and 2016, from 6.4% (19/296) to 17.3% (89/513) (p < 0.001). This trend was seen in both intensive care units and emergency departments. Concurrently, the proportion of ST131 among ESBL-producing E. coli also increased significantly, from 31.6% (6/19) in 2006 to 73.0% (65/89) in 2016 (p = 0.03). Among ESBL-producing E. coli, significant resistance was noted to multiple antimicrobial classes. Comparable increases in the proportion of ESBL-producing K. pneumoniae, K. oxytoca and P. mirabilis were not noted. INTERPRETATION: We observed a significant increase in the proportion of ESBL-producing E. coli in bloodstream infections in Toronto temporally correlated with an increase in the ST131 clonal type. Recognition of this dramatic rise is important to inform empiric antibiotic treatment. Copyright 2018, Joule Inc. or its licensors.
BACKGROUND: Enterobacteriaceae that produce extended-spectrum β-lactamase (ESBL) have emerged as a serious threat, with variable rates depending on geographic region. We determined the prevalence of ESBL-producing Escherichia coli, Klebsiella pneumoniae, K. oxytoca and Proteus mirabilis in bloodstream infections in Toronto from 2006 through 2016. METHODS: All patients with E. coli, K. pneumoniae, K. oxytoca and P. mirabilis isolated from blood in a tertiary care microbiology laboratory in Toronto between 2006 and 2016 (1 isolate per species per patient per year) were included in this retrospective cohort study. Organisms were identified by conventional methods, and susceptibility testing was performed according to Clinical and Laboratory Standards Institute standards. Screening for ESBL and phenotypic confirmatory testing were done with a modified Clinical and Laboratory Standards Institute method. ST131 clonal type was determined by means of an established protocol. RESULTS: The proportion of ESBL-producing E. coli isolates increased significantly between 2006 and 2016, from 6.4% (19/296) to 17.3% (89/513) (p < 0.001). This trend was seen in both intensive care units and emergency departments. Concurrently, the proportion of ST131 among ESBL-producing E. coli also increased significantly, from 31.6% (6/19) in 2006 to 73.0% (65/89) in 2016 (p = 0.03). Among ESBL-producing E. coli, significant resistance was noted to multiple antimicrobial classes. Comparable increases in the proportion of ESBL-producing K. pneumoniae, K. oxytoca and P. mirabilis were not noted. INTERPRETATION: We observed a significant increase in the proportion of ESBL-producing E. coli in bloodstream infections in Toronto temporally correlated with an increase in the ST131 clonal type. Recognition of this dramatic rise is important to inform empiric antibiotic treatment. Copyright 2018, Joule Inc. or its licensors.
Authors: Anand Kumar; Daniel Roberts; Kenneth E Wood; Bruce Light; Joseph E Parrillo; Satendra Sharma; Robert Suppes; Daniel Feinstein; Sergio Zanotti; Leo Taiberg; David Gurka; Aseem Kumar; Mary Cheang Journal: Crit Care Med Date: 2006-06 Impact factor: 7.598
Authors: Kimberly K Scarsi; Joe M Feinglass; Marc H Scheetz; Michael J Postelnick; Maureen K Bolon; Gary A Noskin Journal: Antimicrob Agents Chemother Date: 2006-10 Impact factor: 5.191
Authors: Anand Kumar; Paul Ellis; Yaseen Arabi; Dan Roberts; Bruce Light; Joseph E Parrillo; Peter Dodek; Gordon Wood; Aseem Kumar; David Simon; Cheryl Peters; Muhammad Ahsan; Dan Chateau Journal: Chest Date: 2009-08-20 Impact factor: 9.410
Authors: Stephen P Hawser; Samuel K Bouchillon; Daryl J Hoban; Robert E Badal; Po-Ren Hsueh; David L Paterson Journal: Antimicrob Agents Chemother Date: 2009-06-08 Impact factor: 5.191
Authors: Priyanka Hastak; Mathieu Fourment; Aaron E Darling; Thomas Gottlieb; Elaine Cheong; John Merlino; Garry S A Myers; Steven P Djordjevic; Piklu Roy Chowdhury Journal: Emerg Microbes Infect Date: 2020-12 Impact factor: 7.163